These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 38991687)

  • 1. Are adverse events higher among patients with acute optic neuritis prescribed glucocorticoids? A retrospective, longitudinal cohort study.
    De Lott LB; Brennan B; Wallace B; Kerber K; Burke JF; Roslin C; Terman S; Andrews C; Waljee AK; Banerjee M
    BMJ Open; 2024 Jul; 14(7):e076801. PubMed ID: 38991687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of Glucocorticoid Use for Acute Optic Neuritis in the United States, 2005-2019.
    De Lott LB; Lin CC; Burke JF; Wallace B; Saukkonen D; Waljee AK; Kerber KA
    Ophthalmic Epidemiol; 2023 Feb; 30(1):88-94. PubMed ID: 35168450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of Long-Term Visual Acuity in a Modern Cohort of Patients With Acute Idiopathic and Multiple Sclerosis-Associated Optic Neuritis.
    Jarocki A; Benard-Seguin E; Gonzalez LA; Costello F; Andrews CA; Kerber K; De Lott LB
    J Neuroophthalmol; 2023 Dec; 43(4):475-480. PubMed ID: 37200095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of race/ethnicity with visual outcomes following acute optic neuritis: an analysis of the Optic Neuritis Treatment Trial.
    Moss HE; Gao W; Balcer LJ; Joslin CE
    JAMA Ophthalmol; 2014 Apr; 132(4):421-7. PubMed ID: 24557028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Corticosteroids for treating optic neuritis.
    Gal RL; Vedula SS; Beck R
    Cochrane Database Syst Rev; 2015 Aug; 2015(8):CD001430. PubMed ID: 26273799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population-based assessment of adverse events associated with long-term glucocorticoid use.
    Curtis JR; Westfall AO; Allison J; Bijlsma JW; Freeman A; George V; Kovac SH; Spettell CM; Saag KG
    Arthritis Rheum; 2006 Jun; 55(3):420-6. PubMed ID: 16739208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patterns of glucocorticoid prescribing and provider-level variation in a commercially insured incident rheumatoid arthritis population: A retrospective cohort study.
    Wallace BI; Lin P; Kamdar N; Noureldin M; Hayward R; Fox DA; Curtis JR; Saag KG; Waljee AK
    Semin Arthritis Rheum; 2020 Apr; 50(2):228-236. PubMed ID: 31522762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cumulative Burden of Glucocorticoid-related Adverse Events in Patients with Systemic Lupus Erythematosus: Findings from a 12-year Longitudinal Study.
    Chen HL; Shen LJ; Hsu PN; Shen CY; Hall SA; Hsiao FY
    J Rheumatol; 2018 Jan; 45(1):83-89. PubMed ID: 29142034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of glucocorticoids and risk of venous thromboembolism: a nationwide population-based case-control study.
    Johannesdottir SA; Horváth-Puhó E; Dekkers OM; Cannegieter SC; Jørgensen JO; Ehrenstein V; Vandenbroucke JP; Pedersen L; Sørensen HT
    JAMA Intern Med; 2013 May; 173(9):743-52. PubMed ID: 23546607
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Side effects of glucocorticoid treatment. Experience of the Optic Neuritis Treatment Trial.
    Chrousos GA; Kattah JC; Beck RW; Cleary PA
    JAMA; 1993 Apr; 269(16):2110-2. PubMed ID: 8468765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of Biologics and Glucocorticoids in Patients With Rheumatoid Arthritis Undergoing Arthroplasty: A Cohort Study.
    George MD; Baker JF; Winthrop K; Alemao E; Chen L; Connolly S; Hsu JY; Simon TA; Wu Q; Xie F; Yang S; Curtis JR
    Ann Intern Med; 2019 Jun; 170(12):825-836. PubMed ID: 31108503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Individual-Level Factors With Visual Outcomes in Optic Neuritis: Secondary Analysis of a Randomized Clinical Trial.
    De Lott LB; Burke JF; Andrews CA; Costello F; Cornblath WT; Trobe JD; Lee PP; Kerber KA
    JAMA Netw Open; 2020 May; 3(5):e204339. PubMed ID: 32379333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adherence to Clinical Trial Supported Evaluation of Optic Neuritis.
    Meer E; Shindler KS; Yu Y; VanderBeek BL
    Ophthalmic Epidemiol; 2019 Oct; 26(5):321-328. PubMed ID: 31140885
    [No Abstract]   [Full Text] [Related]  

  • 15. Real-world management of patients with neuromyelitis optica spectrum disorder using satralizumab: Results from a Japanese claims database.
    Nakashima I; Nakahara J; Yasunaga H; Yamashita M; Nishijima N; Satomura A; Nio M; Fujihara K
    Mult Scler Relat Disord; 2024 Apr; 84():105502. PubMed ID: 38401202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Treating Acute Optic Neuritis With Bioequivalent Oral vs Intravenous Corticosteroids: A Randomized Clinical Trial.
    Morrow SA; Fraser JA; Day C; Bowman D; Rosehart H; Kremenchutzky M; Nicolle M
    JAMA Neurol; 2018 Jun; 75(6):690-696. PubMed ID: 29507942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence and Causes of Overdiagnosis of Optic Neuritis.
    Stunkel L; Kung NH; Wilson B; McClelland CM; Van Stavern GP
    JAMA Ophthalmol; 2018 Jan; 136(1):76-81. PubMed ID: 29222573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial.
    Cadavid D; Balcer L; Galetta S; Aktas O; Ziemssen T; Vanopdenbosch L; Frederiksen J; Skeen M; Jaffe GJ; Butzkueven H; Ziemssen F; Massacesi L; Chai Y; Xu L; Freeman S;
    Lancet Neurol; 2017 Mar; 16(3):189-199. PubMed ID: 28229892
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optic neuritis treatment trial. One-year follow-up results.
    Beck RW; Cleary PA
    Arch Ophthalmol; 1993 Jun; 111(6):773-5. PubMed ID: 8512477
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Visual outcome after intravenous dexamethasone therapy for idiopathic optic neuritis in an Indian population: a clinical case series.
    Sethi HS; Menon V; Sharma P; Khokhar S; Tandon R
    Indian J Ophthalmol; 2006 Sep; 54(3):177-83. PubMed ID: 16921215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.